MedTrace Logo

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT04671251 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-02-29

No results posted yet for this study

Summary

This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma.

The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.

Conditions

Interventions

DRUG

AEVI-007

50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.

Sponsors & Collaborators

  • Avalo Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Manish Patel, MD · Florida Cancer Specialist

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2022-03-30
Completion
2022-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04671251 on ClinicalTrials.gov